Which cancer drug is safer for the heart? large study aims to find out
NCT ID NCT07283965
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at medical records of 15,000 adults with chronic B-cell cancers to compare the risk of developing atrial fibrillation (an irregular heartbeat) between two drugs, zanubrutinib and acalabrutinib. Researchers will analyze data from a health database to see which drug is linked to fewer heart problems. The goal is to help doctors choose the safer treatment option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BTK INHIBITORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Could a simple health chat slash heart disease and cancer risk?
- One scan, many answers: can a new CT predict heart risks after stenting?
- Digital coaching aims to boost heart health in obesity
- Can a new device suck out deadly lung clots?